Abbott’s Xience everolimus-eluting stent has joined the group of drug-eluting coronary stents approved by the US Food and Drug Administration for patients at high risk of bleeding.
On 30 June, the company announced the FDA approval for an expanded indication for the Xience line of stents that includes patients at high risk of bleeding, including those who can only stay on dual-antiplatelet (DAPT) drug therapy for 28 days. The Xience stents earned a CE mark for the same high-risk patients in April
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?